The area of research for our group is malignant lymphomas – all possible aspects, aiming for the improvement of the quality of life and survival of these patients. The paradigm behind most of current health care is evidence –based medicine. This is regarded as the optimal way of utilizing resources on a population level, as well as for individual treatment decisions. The evidence basis is primarily derived from clinical trials, but data can also be extracted from alternate sources such as national or regional data registries. The objective of our research is to expand this evidence basis, currently through three strategies:

1. The development of cIinical trials - we have been involved in all stages of trials for lymphoma, and designed, conducted and initiated several. Most of these are conducted on a Nordic level, but recently also involving other European countries, as well as in the Asia-Pacific.

2. Clinical epidemiology – using data from the Swedish Lymphoma Registry to provide clinically useful real world data on treatment and prognosis, in many cases in collaboration with Nordic colleagues. 

3. Translational research – to identify predictive biomarkers for treatment decision – by immunohistochemistry, gene expression or sequencing.